These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1316 related articles for article (PubMed ID: 25872593)

  • 21. Alcohol, liver disease and the gut microbiota.
    Bajaj JS
    Nat Rev Gastroenterol Hepatol; 2019 Apr; 16(4):235-246. PubMed ID: 30643227
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Microbiota-based treatments in alcoholic liver disease.
    Sung H; Kim SW; Hong M; Suk KT
    World J Gastroenterol; 2016 Aug; 22(29):6673-82. PubMed ID: 27547010
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Gut microbiota and host metabolism in liver cirrhosis.
    Usami M; Miyoshi M; Yamashita H
    World J Gastroenterol; 2015 Nov; 21(41):11597-608. PubMed ID: 26556989
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Gut microbiota in alcoholic liver disease: pathogenetic role and therapeutic perspectives.
    Malaguarnera G; Giordano M; Nunnari G; Bertino G; Malaguarnera M
    World J Gastroenterol; 2014 Nov; 20(44):16639-48. PubMed ID: 25469033
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Intestinal HIF-1α deletion exacerbates alcoholic liver disease by inducing intestinal dysbiosis and barrier dysfunction.
    Shao T; Zhao C; Li F; Gu Z; Liu L; Zhang L; Wang Y; He L; Liu Y; Liu Q; Chen Y; Donde H; Wang R; Jala VR; Barve S; Chen SY; Zhang X; Chen Y; McClain CJ; Feng W
    J Hepatol; 2018 Oct; 69(4):886-895. PubMed ID: 29803899
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antimicrobial proteins: intestinal guards to protect against liver disease.
    Hendrikx T; Schnabl B
    J Gastroenterol; 2019 Mar; 54(3):209-217. PubMed ID: 30392013
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Review article: the gut microbiome as a therapeutic target in the pathogenesis and treatment of chronic liver disease.
    Woodhouse CA; Patel VC; Singanayagam A; Shawcross DL
    Aliment Pharmacol Ther; 2018 Jan; 47(2):192-202. PubMed ID: 29083037
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Is intestinal inflammation linking dysbiosis to gut barrier dysfunction during liver disease?
    Brandl K; Schnabl B
    Expert Rev Gastroenterol Hepatol; 2015; 9(8):1069-76. PubMed ID: 26088524
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The intestinal microbiome and the leaky gut as therapeutic targets in alcoholic liver disease.
    Hartmann P; Chen WC; Schnabl B
    Front Physiol; 2012; 3():402. PubMed ID: 23087650
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The intestinal microbiota as a therapeutic target in the treatment of NAFLD and ALD.
    Huang W; Kong D
    Biomed Pharmacother; 2021 Mar; 135():111235. PubMed ID: 33561650
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The gut-liver axis in liver disease: Pathophysiological basis for therapy.
    Albillos A; de Gottardi A; Rescigno M
    J Hepatol; 2020 Mar; 72(3):558-577. PubMed ID: 31622696
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Gut Microbiota and Alcoholic Liver Disease.
    Scarpellini E; Forlino M; Lupo M; Rasetti C; Fava G; Abenavoli L; De Santis A
    Rev Recent Clin Trials; 2016; 11(3):213-9. PubMed ID: 27515958
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunoglobulin A and liver diseases.
    Inamine T; Schnabl B
    J Gastroenterol; 2018 Jun; 53(6):691-700. PubMed ID: 29075899
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bacterial translocation in patients with liver cirrhosis: physiology, clinical consequences, and practical implications.
    Ponziani FR; Zocco MA; Cerrito L; Gasbarrini A; Pompili M
    Expert Rev Gastroenterol Hepatol; 2018 Jul; 12(7):641-656. PubMed ID: 29806487
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Gut-liver axis, cirrhosis and portal hypertension: the chicken and the egg.
    Arab JP; Martin-Mateos RM; Shah VH
    Hepatol Int; 2018 Feb; 12(Suppl 1):24-33. PubMed ID: 28550391
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bidirectional Communication between Liver and Gut during Alcoholic Liver Disease.
    Stärkel P; Schnabl B
    Semin Liver Dis; 2016 Sep; 36(4):331-339. PubMed ID: 27997973
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Microbiota, Liver Diseases, and Alcohol.
    Cassard AM; Gérard P; Perlemuter G
    Microbiol Spectr; 2017 Aug; 5(4):. PubMed ID: 28840806
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Microbiota and the gut-liver axis: bacterial translocation, inflammation and infection in cirrhosis.
    Giannelli V; Di Gregorio V; Iebba V; Giusto M; Schippa S; Merli M; Thalheimer U
    World J Gastroenterol; 2014 Dec; 20(45):16795-810. PubMed ID: 25492994
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Gut-liver axis and probiotics: their role in non-alcoholic fatty liver disease.
    Paolella G; Mandato C; Pierri L; Poeta M; Di Stasi M; Vajro P
    World J Gastroenterol; 2014 Nov; 20(42):15518-31. PubMed ID: 25400436
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Rice Bran Phenolic Extract Protects against Alcoholic Liver Injury in Mice by Alleviating Intestinal Microbiota Dysbiosis, Barrier Dysfunction, and Liver Inflammation Mediated by the Endotoxin-TLR4-NF-κB Pathway.
    Xiao J; Zhang R; Wu Y; Wu C; Jia X; Dong L; Liu L; Chen Y; Bai Y; Zhang M
    J Agric Food Chem; 2020 Feb; 68(5):1237-1247. PubMed ID: 31722525
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 66.